ClinicalTrials.gg
CompletedNCT07932574SDT-SLNBUpdated Nov 12, 2026

Single Tracer Versus Dual Tracer Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer : A Comparative Study

An interventional study of single tracer sentinel lymph node biopsy and Dual Tracr Sentinel lymph node biopsy in Breast Neoplasm, sponsored by King Edward Medical University. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by King Edward Medical University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Apr 2026, registered Oct 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Breast Neoplasms with a site in Pakistan — 8 open to participants now, 14 under way, none of them phase 3. Breast Neoplasms · Pakistan.

Enrollment
21st of 39
110 · median 120
Started
2026
with 6 others
No phase
25 of 52
6 open now
Registered
52nd of 52
by date

Among the 52 studies in Breast Neoplasms with a site in Pakistan, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2026, is one of 25 with no phase, and was the 52nd registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 52 studies in Breast Neoplasms with a site in Pakistan are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Breast Neoplasms with a site in Pakistan, or all of them as a file.
02

Study summary

This study aim to compare the accuracy of single tracer versus dual tracer sentinel lymph node biopsy in breast carcinoma patients who have clinically positive axillary lymph nodes before neoadjuvant chemotherapy and become clinically node negative after treatment. this study evaluate sentinel lymph node identification and detection rates to determines whether single tracer sentinel lymph node biopsy provides comparable results to the dual tracer technique

Read the detailed description

Sentinel lymph node biopsy (SLNB) has become the standard method for axillary staging in clinically node-negative breast cancer, replacing axillary lymph node dissection (ALND) due to lower morbidity with equivalent oncologic outcomes . However, the role of SLNB after neoadjuvant chemotherapy (NACT) is technically challenging because chemotherapy alters lymphatic drainage, resulting in lower identification rates and higher false-negative rates compared with upfront surgery.

Large prospective trials, including the SENTINA, ACOSOG Z1071, and SN FNAC studies, have demonstrated that the use of dual-tracer techniques (radioisotope plus blue dye) and retrieval of multiple sentinel lymph nodes significantly improves detection rates and reduces false-negative rates in the Post-NACT setting .

Based on this evidence, international guidelines from NCCN, ASCO, and ESMO recommend the use of dual-tracer SLNB after NACT, particularly in patients who were initially node-positive.

Despite these recommendations, access to radioisotopes and gamma probes remains limited in low- and middle-income countries such as Pakistan. Consequently, single-tracer SLNB using blue dye alone continues to be practiced in many centers. Emerging observational studies suggest that in carefully selected patients who convert to clinically and radiologically node-negative status after NACT, single-tracer SLNB may still achieve acceptable detection rates .

However, local data evaluating the performance of single-tracer versus dual-tracer SLNB exclusively in the post-NACT setting are scarce. This study aims to address this gap by comparing both techniques in patients with clinically and radiologically negative axilla following neoadjuvant chemotherapy.

Post-NACT axillary staging remains a critical and guideline-sensitive aspect of breast cancer management. While dual-tracer SLNB is recommended to reduce false-negative rates, its routine use is limited by availability and cost in resource-constrained settings. Evaluating the feasibility and outcomes of single-tracer SLNB in post-NACT patients is therefore essential to guide safe, cost-effective, and locally applicable axillary management strategies .

OBJECTIVES:

To compare the effectiveness of single tracer versus dual tracer technique for sentinel lymph node biopsy in breast cancer patients who were node-positive before neoadjuvant chemotherapy and become clinically node-negative after chemotherapy, using axillary lymph node dissection as the reference standard.

To compare sentinel lymph node identification rate between single tracer and dual tracer techniques in ycN0 breast cancer patients.

To compare the number of sentinel lymph nodes retrieved using single versus dual tracer techniques.

To determine the false negative rate of sentinel lymph node biopsy in both groups using axillary lymph node dissection as the gold standard.

To compare operative time and procedure-related complications between the two techniques.

OPERATIONAL DEFINITION:

Sentinel Lymph Node (SLN) A sentinel lymph node is defined as the first axillary lymph node(s) that receive lymphatic drainage from the primary breast tumor, identified intraoperatively by uptake of blue dye and/or radioisotope.

Sentinel Lymph Node Biopsy (SLNB) SLNB refers to the surgical removal of sentinel lymph node(s) for histopathological evaluation in breast cancer patients for axillary staging after neoadjuvant chemotherapy.

Single-Tracer Technique Single-tracer SLNB is defined as identification of sentinel lymph node(s) using blue dye alone, injected peri - tumour or peri-areolar prior to surgery, without the use of radioisotope or gamma probe.

Dual-Tracer Technique Dual-tracer SLNB is defined as identification of sentinel lymph node(s) using a combination of blue dye and radioisotope (technetium-99m) with intraoperative localization using a gamma probe.

Post-Neoadjuvant Chemotherapy (Post-NACT) Post-NACT refers to patients who have completed all planned neoadjuvant systemic chemotherapy prior to definitive breast surgery.

Clinically Node-Negative Axilla (cN0) After NACT Clinically node-negative axilla is defined as absence of palpable axillary lymph nodes on physical examination after completion of neoadjuvant chemotherapy.

Radiologically Node-Negative Axilla After NACT

Radiologically node-negative axilla is defined as no suspicious axillary lymph nodes on ultrasound ± mammography or MRI, characterized by:

Preserved fatty hilum Cortical thickness ≤3 mm Absence of abnormal nodal morphology

Sentinel Lymph Node Detection Rate (Identification Rate) Sentinel lymph node detection rate will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery after tracer injection.

It will be calculated as: Detection Rate =(Number of patients in whom ≥1 sentinel lymph node is identified) ÷(Total number of patients undergoing sentinel lymph node biopsy) × 100 Detection rate will be compared between single tracer and dual tracer groups. Failure of Sentinel Lymph Node Detection Failure of sentinel lymph node detection will be defined as the inability to identify any sentinel lymph node during surgery after tracer injection, requiring direct progression to axillary lymph node dissection.

Failure Rate =(Number of patients in whom no sentinel lymph node is identified) ÷ (Total number of patients undergoing SLNB) × 100 False Negative Sentinel Lymph Node Biopsy A false negative result will be defined when Sentinel lymph node biopsy shows no metastasis ,but axillary lymph node dissection reveals metastatic lymph nodes.

False Negative Rate (FNR)

False negative rate will be calculated as:

FNR =False Negatives ÷ (False Negatives + True Positives) × 100 ycN0 Status ycN0 will be defined as clinically and radiologically negative axillary lymph nodes after completion of neoadjuvant chemotherapy, assessed by: Clinical examination Axillary ultrasound ± imaging in patients who were biopsy-proven node-positive prior to chemotherapy.

Axillary Lymph Node Dissection (ALND) Axillary lymph node dissection will be defined as surgical removal of level I and level II axillary lymph nodes, performed in all study patients after sentinel lymph node biopsy to serve as the reference standard for nodal status.

Statistical Significance Statistical significance is defined as a p-value less than 0.05.

HYPOTHESIS:

The dual tracer technique has a higher sentinel lymph node identification rate and lower false-negative rate compared with the single tracer technique in breast cancer patients who become ycN0 after neoadjuvant chemotherapy.

MATERIAL AND METHODS:

STUDY DESIGN: Comparative Cross-Sectional Study STUDY POPULATION: Female breast cancer patients who have received neoadjuvant chemotherapy and are planned for sentinel lymph node biopsy.

SETTING: The study will be conducted in Breast Surgery Unit, Mayo Hospital, Lahore.

DURATION OF STUDY: Six Months after the approval of synopsis SAMPLING TECHNIQUE: Non Probability Convenient Sampling SAMPLE SIZE: Sample size of 108 patients (54 patients in each group) is estimated by using 5% level of significance, 90% power of test with expected mean value of positive lymph node in dual tracer as 4±2 and single tracer as 5±3.

The sample size was calculated using the following formula:

Where:

2 = Variance z1-α = Confidence level 95% =1.96 z1-β = Power of Test 90%

  1. = Population mean I = 4
  2. = Population mean II = 5

SAMPLE SELECTION:

Female breast cancer patients who have received neoadjuvant chemotherapy and are planned for sentinel lymph node biopsy.

DATA COLLECTION PROCEDURE:

A total of 110 patients fulfilling the inclusion criteria will be admitted from breast surgery unit, Mayo hospital Lahore. Ethical approval will be obtained from the Institutional Review Board. Written informed consent will be taken from all patients. Confidentiality will be maintained throughout the study. Female breast cancer patients who have positive axillary node and clipped that node received neoadjuvant chemotherapy and are planned for sentinel lymph node biopsy are randomly selected through lottery method. Patients will be divided into two groups:

Group A: Single-tracer SLNB( Isosulfan blue dye alone) Group B: Dual-tracer SLNB (radioisotope plus isosulfan blue dye) Blue dye will be injected peritumorally or periareolar30 minutes before anesthesia, while radioisotope injection will be injected 2 hours before surgery. Sentinel lymph nodes will be identified intra-operatively using blue dye visualization and gamma probe detection. Frozen section analysis will be performed .The number of nodes retrieved and intra-operative findings will be recorded. All identified sentinel lymph nodes will be excised and labeled separately .Following sentinel lymph node biopsy, all patients will undergo completion axillary lymph node dissection (ALND) irrespective of sentinel node status .All removed lymph nodes will be sent for histopathological examination.

The results of sentinel lymph node biopsy will be compared with single verses dual- tracer and the findings of axillary lymph node dissection to determine: Identification rate, False negative rate, number of sentinel lymph node retrieved, operative time, procedure related complications, residual nodal disease rate on ALND. All the data will be collected through a pre-designed performa (attached). Follow up of patients will be 1st at 3 month 2nd at 6 month.

DATA ANALYSIS PRODECURE:

Data will be entered and analyzed by using spss v26.0. Continuous variables such as age, tumor size, number of sentinel lymph nodes retrieved, and operative time will be presented as mean ± standard deviation or median with interquartile range depending on data distribution. Comparison between the two groups will be performed using the independent t-test or Mann-Whitney U test.

Categorical variables such as sentinel lymph node identification rate, sentinel lymph node positivity, false-negative rate, and procedure-related complications will be expressed as frequencies and percentages. Comparisons between groups will be performed using the Chi-square test or Fisher's exact test where appropriate.

The findings of sentinel lymph node biopsy will be compared with axillary lymph node dissection (gold standard) to calculate :False negative rate (FNR).A p-value ≤ 0.05 will be considered statistically significant.

03

Conditions studied

  • Breast Neoplasm

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged ≥18 years.
  • proven breast carcinoma.
  • Received chemotherapy.
  • Clinically node-negative axilla after NACT.
  • Radiologically node-negative axilla after NACT.
  • Planned for sentinel lymph node .

Exclusion criteria

Exclusion Criteria:

  • Persistent clinically node-positive disease after NACT.
  • Previous axillary surgery.
  • Distant disease.
  • Pregnancy or lactation.
  • Known allergy to tracer agents.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Active comparator
    single tracer using blue dye alone

    By Using 1.5 cc Blue dye and inject sub dermal in peri areolar , retroareolar and peritumoural area about 20 mints before start of surgery

    Procedure: single tracer sentinel lymph node biopsy

  • Active comparator
    Dual tracer use blue dye plus radioisotope

    Radioisotope dye inject subdermally at 4 point 3, 6, 9,12 o clock periareolar area 3hrs before surgery and then just 20 mint before surgery inject 1.5 cc of isosulfan blue subdermal periareolar area or retroarelar area

    Procedure: Dual Tracr Sentinel lymph node biopsy

Interventions

  • Proceduresingle tracer sentinel lymph node biopsy

    By Using 1.5 cc Blue dye and inject sub dermal in peri areolar , retroareolar and peritumoural area about 20 mints before start of surgery

  • ProcedureDual Tracr Sentinel lymph node biopsy

    radio isotope dye inject at 4 point 3,6,9,12 periareolar subdermal 3 hrs before surgery and isosulfan blue dye injected 20 mint before surgery at periareolar area subdermally

06

What researchers measure

Primary outcomes

  1. Sentinel Lymph Node Identification Rate:It will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery using either single tracer or dual tracer technique.

    Sentinel Lymph Node Identification Rate:It will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery using either single tracer or dual tracer technique.Identification rate will be calculated as:This outcome will be compared between the single tracer group and dual tracer group.

    Time frame: peri operatively at the time of sentinel lymph node biopsy , following administration of the allocated single or dual tracer technique

Secondary outcomes

  1. false negative rate of sentinel lymph node biopsy

    False negative rate will be defined as the proportion of patients in whom sentinel lymph node biopsy is negative but axillary lymph node dissection reveals metastatic lymph nodes.

    Time frame: within 10 days after surgery, following availability of final histopathological results of completion axillary lymph node dissection specimens

  2. Number of Sentinel Lymph Nodes:

    Number of sentinel lymph nodes Retrieved The total number of sentinel lymph nodes removed during surgery will be recorded and compared between the single tracer and dual tracer groups

    Time frame: with in 1 hrs after histopathology Report of sentinel lymph node biopsy recieved

  3. Operative Time:

    The time required to identify and retrieve sentinel lymph nodes will be recorded and compared between both groups.

    Time frame: From the start of surgical procedure to completion of procedure measured intraoperativley and recorded in minutes

Other outcomes

  1. Incidence of Procedure-Related Complications

    The proportion of patients experiencing procedure-related complications, including allergic reactions to the tracer or dye, seroma, surgical site infection, and lymphoedema, will be assessed and compared between the single-tracer and dual-tracer groups. Results will be reported as the number and percentage of patients experiencing each complication.

    Time frame: From the time of surgery until 30 days postoperatively.

07

Study locations

1 site
  • King Edward Medical University
    Lahore, Punjab Province 54000, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Oct 2026, 5 months.

Of 2,666 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 5 months is below that.

Counting every sponsor, half of 2,776 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Nov 12, 2026
StartActual
Apr 28, 2026
Primary completionActual
Oct 1, 2026
CompletionActual
Oct 1, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07932574
Lead sponsor
King Edward Medical University
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Apr 28, 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion